[关键词]
[摘要]
伊特卡赛肽(商品名为ParsabivTM)是安进公司开发的新型二代拟钙剂,主要用于治疗慢性肾病继发性甲状旁腺机能亢进。伊特卡赛肽通过直接与钙感应受体结合来降低血钙浓度,还可以降低甲状旁腺素的水平。欧盟于2016年11月批准注射用伊特卡赛肽用于慢性肾病继发性甲状旁腺机能亢进的透析患者。介绍该药的药理作用、药动学、临床试验及不良反应研究概况。
[Key word]
[Abstract]
Etelcalcetide (ParsabivTM) is a second generation calcimimetic agent newly developed by Amgen, mainly used for the treatment of secondary hyperparathyroidism. Etelcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor, but also reduces the parathyroid hormone level. The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection. This paper summarized the pharmacological effects, pharmacokinetics, clinical trials, and adverse reaction of Etelcalcetide.
[中图分类号]
[基金项目]